在多发性硬化症的免疫复合疗法后,新的自身免疫疾病的发展
Nataša Giedraitienė1, Rasa Kizlaitienė2, Gintaras Kaubrys2
1Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. natasa.giedraitiene@gmail.com.
Scientific reports
|December 27, 2024
概括
免疫复合疗法 (IRT) 可以导致多发性硬化症 (MS) 患者出现新的自身免疫性疾病 (AD). 与克拉德里宾相比,阿勒姆图祖马布和自身造血干细胞移植显示出更高的ADS风险.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 免疫复合疗法 (IRT) 提供了一种高度有效的治疗多发性硬化症 (MS).
- 在某些IRT后,可能会出现二次自身免疫性疾病 (ADs),需要进一步调查.
- 了解IRT后ADS的发生率和特征对于患者管理至关重要.
研究的目的:
- 评估在IRT后MS患者中新的AD发展的发生率.
- 描述在IRT之后出现的AD类型.
- 为了确定这些二次ADs的发病时间.
主要方法:
- 对179名复发性多发性硬化症患者的回顾性分析,这些患者在十年内接受了IRT治疗.
- 将IRT分类为自身造血干细胞移植 (AHSCT),阿勒姆图祖马布 (ALE) 和克拉德里宾 (CLA).
- 监测和记录新的AD发展和治疗后出现的时间.
主要成果:
- 总体AD发病率因IRT而异:在AHSCT后为16.2%,在ALE后为42.1%,在CLA后为1.6%.
- 艾滋病在阿姆图祖马布治疗后出现较早,但在AHSCT治疗后出现较晚 (不包括细胞衰竭).
- 阿拉姆图祖马布和AHSCT与MS患者中二次ADS的风险较高有关.
结论:
- 神经科医生必须保持警,以寻找二次性AD的发展,在MS患者治疗阿勒姆图祖马布和AHSCT.
- 在各种IRT模式中,ADs的风险和时间有很大差异.
- 对IRT后AD的机制和管理进行进一步研究是有必要的.
相关概念视频
Autoimmune Disorders
313
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
313
T Cell Types and Functions
613
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
613
Immunodeficiency Diseases
823
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
823
Myasthenia Gravis: Overview and Treatment
932
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
932
Cell-mediated Immune Responses
65.0K
Overview
65.0K


